MYC activation is a known hallmark of cancer as it governs the gene targets involved in
various facets of cancer progression. Of interest, MYC governs oncometabolism through the …

Simple Summary While both the fields of cancer metastasis research and cancer
immunology have been heavily investigated, their combination—the immunology of …

Immunotherapy has revolutionized the established therapeutics against tumors. As the
major immunotherapy approach, immune checkpoint inhibitors (ICIs) achieved remarkable …

Background: Cancer therapeutics have a low success rate in clinical trials. An
interdisciplinary approach is needed to translate basic, clinical, and remote fields of …

Natural killer (NK) cell immunotherapies for cancer can complement existing T cell therapies
while benefiting from advancements already made in the immunotherapy field. For NK cell …

Metabolic adaptation of cancer cells is a key tactic for maintaining their tumorigenicity and
viability in the tumor immune microenvironment (TIME). Concurrent modulation on the …

Cancer metastasis remains the most lethal characteristic of tumors mediating the majority of
cancer-related deaths. Identifying key molecules responsible for metastasis, understanding …

For over a century, we have appreciated that the biochemical processes through which
micro-and macronutrients are anabolized and catabolized—collectively referred to as …

Background E2F transcription factors are well‐recognized oncogenic molecules, and their
correlation with immune cell infiltration has recently been reported. This work studies the …

Deregulation of metabolism and resistance to cell death are two hallmarks of cancer [1]. A
plethora of genetic and non-genetic processes tightly control catabolic and anabolic …